DRUG DOSAGE/ROU CLASSIFICATIO MECHANIS INDICATION CONTRAINDICATIO NSG.

TE NS M OF S NS RESPONSIBILITI
ACTION ES

Tranexam 1gram Antifibrinolytic Tranexamic General: > Hypersensitivity Before:

ic Acid IVTT,q8hrs x 3 acid > treatment of > Active > check the
doses competitivel excessive Intravascular Clotting doctor’s order
y inhibits bleeding > Acquired defective > Observe the 15
activation of resulting from color vision rights of drug
plasminoge systemic or > Subarachnoid administration
n (via local Hemorrhage > Do skin testing
binding to hyperfibrinoly > Tell patient to
the kringle sis inform the
domain), > prophylaxis healthcare
thereby in patients Precautions: provider if color
reducing with Use cautiously with blind, have a
conversion coagulopathy renal impairment, history of stroke,
of undergoing hematuria originating and blood clot, or
plasminoge surgical in the upper urinary bleeding in your
n to plasmin procedures tract; and conditions brain.
(fibrinolysin) associated with > Caution patient
, an increased thrombus to avoid products
enzyme formation containing aspirin
that or NSAIDs
degrades > For women who
fibrin clots, are taking to
fibrinogen, Patient’s control heavy
and other actual bleeding, the
plasma indication: medication should
proteins, Treatment of only be taken
including excessive during the
the bleeding menstrual period
procoagula resulting from
nt factors V systemic or During:
and VIII local > administer the
hyperfibrinoly drug at the right
sis dosage and route
in the right time
> check the
patency of the IV
site and IV line
> Do not use this
medication
without telling
your doctor if you
are breastfeeding
a baby

After:
> Advise patient to
take medication
exactly as
directed
> Unusual change
in bleeding pattern
should be
reported to the
physician
> Report severe
allergic reactions
such as rash,
hives, itching,
dyspnea,
 tightness in the
chest, swelling of
the mouth, face,
lips or tongue
> If the patient
missed a dose, let
patient take when
remembered, then
take next dose at
least 6 hours later.
> Store this
medication at
room temperature
away from
moisture and heat

Furosemi 40mg IVVT, Diuretics Inhibits the Oral, IV: Severe sodium and ● asses fluid
de q24hrs reabsorptio Edema water depletion, status (monitor
associated hypersensitivity to daily weight, input
n of sodium
with CHF, sulphonamides and and output)
and cirrhosis, furosemide, ● monitor blood
chloride renal disease hypokalaemia, pressure and
from the IV: Acute hyponatraemia, pulse before
loop pulmonary precomatose states administration-
of henle edema associated with liver this is to
and distal Oral: cirrhosis, anuria or determine
Hypertension renal failure. compliance in
renal
Addison’s disease. patients treated
tubule. Avoid with patients with hypertension
Increases with alcohol ● assess patients
renal intolerance receiving digoxin
excretion of for anorexia,
water, nausea, vomiting,
sodium, muscle cramps,
chloride, and confusion.
magnesium ● assess patients
, potassium for tinnitus and
and hearing loss.
calcium. ● assess for
allergy to
sulphonamides
● Monitor blood
glucose closely;
may cause
increased blood
glucose level
● Caution patient
to change
positions slowly to
minimize
orthostatic
hypotension.
● Advise patient
to contact health
care professional
immediately if
muscle weakness,
cramps, nausea,
dizziness and
numbness occurs.
● Caution older
patients or their
caregivers about
increased risk for
 falls.
●Furosemide is
often given in
conjunction with a
potassium
supplement or a
potassium-sparing
diuretic to
counteract
potassium loss.

Hydralazi 5g, IVTT Antihypertensive Acts directly General Concentrations Before

ne on vascular Indications - Hypersensitivity - Check blood
smooth - - CAD pressure.
muscle to Hypertension - mitral valvular - Arrange for
cause - Eclampsia rheumatic heart CBC, LE cell
vasodilation disease preparations, and
, primarily ANA titers before
arteriolar, Precaution therapy.
decreasing - with CAV’s - Assess for
peripheral - increased contraindicated
resistance; intracranial pressure conditions.
maintains - severe - Observe the 15
or hypertension with rights of drug
increases uremia administration.
renal and - advanced renal - Assess bowel
cerebral damage sounds.
flow. - slow acetylators - Assess voiding
- lactation pattern.
- pregnancy
- pulmonary During
hypertension - Give oral drug
with food.
- Use parenteral
drug immediately
after opening
ampule.
- Discard
discolored
solutions.
- Arrange for
CBC, LE cell
preparations, and
ANA titers during
prolonged
therapy.
- Instruct to take
drug exactly as
prescribed.

After
- Withdraw drug
gradually.
- Discontinue if
blood dyscrasias
occur.
- Arrange for
pyridoxine therapy
if patient develops
symptoms of
peripheral neuritis.
- Monitor for
orthostatic
hypotension.
- Report persistent
or severe
constipation,
unexplained fever
or malaise,
muscle or joint
aching, chest
pain, rash,
numbness,
tingling.
- Do proper
documentation.